Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > ONC the promise that never fulfills
View:
Post by GOBOGOH on Feb 17, 2021 1:01pm

ONC the promise that never fulfills

I have had this dog excrement of stock for years.   It is always almost there.  At the beginning of last, the common believe that there would not be an approved covid 19 vac. for 3 to 5 years.  It took less then a year for the first two and now there are several - with two or 3 with new technology.

So someone explain to me how ONC can go on for years with no real break through?  Always on the cusp of something great.  I have heard nothing but hollow promises and hype, and, I don't see how this is any different.
Comment by askretka on Feb 17, 2021 1:32pm
Injecting live virus into people has akways been controversial. The new research report says that the technology to administer the virus safely and measure the effects is finally here. You can't really compare Injecting a virus as a therapy which is totally new. To making a COVID-19 vaccine. We've been making vaccines for almost a hundred years.
Comment by westcoast1000 on Feb 17, 2021 2:03pm
GOBO There is so much missing in the reasoning of your post it is hard to give a reply. In breif, the mRNA technology just recently allows developers to in essence imitate or fake the virus and thus create a vaccine. The ONCY role in immunology has developed enormously in the last three years. It is a whole new market context.  The two are wildly different.
Comment by GOBOGOH on Feb 17, 2021 2:50pm
Westcoast, I know the examples are not the same - I referencing timeframes - ONC has been around a lot longer then 3 years and the big break through was supposed to happen yours ago.  Maybe it will happen now, maybe not.  Their track record is not impressive in terms of stock performance -  the reverse split didn't help the shareholder.  But, this could just be sour grapes ...more  
Comment by JohnnyYeg on Feb 17, 2021 3:12pm
So in other words, you were expecting a sure thing, following the progression YOU wanted, and in the timeline that YOU expected? And in a clinical biotech development company?? Interesting.
Comment by GOBOGOH on Feb 17, 2021 4:14pm
JohnnyYeg, Not really, I was following what the company said, forecasted, etc.  It has just never happened.  I lost more on other speculative stocks and also made a lot on other stocks.  I just don't believe these guys anymore - they just always seem to developing and not developed.  To quote an old song: "I thought you was the one but your bread ain't ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities